Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
<strong>Background/objective </strong>The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment. <br><strong> Methods <...
المؤلفون الرئيسيون: | Coates, LC, Smolen, JS, Mease, PJ, Husni, ME, Merola, JF, Lespessailles, E, Kishimoto, M, Macpherson, L, Bradley, AJ, Bolce, R, Helliwell, PS |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
BMJ Publishing Group
2022
|
مواد مشابهة
-
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
حسب: Josef S Smolen, وآخرون
منشور في: (2022-11-01) -
Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
حسب: Coates, L, وآخرون
منشور في: (2018) -
Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
حسب: Coates, LC, وآخرون
منشور في: (2021) -
Ixekizumab in the treatment of psoriatic arthritis
حسب: Yu. L. Korsakova, وآخرون
منشور في: (2024-12-01) -
Methotrexate in psoriasis and psoriatic arthritis
حسب: Coates, L, وآخرون
منشور في: (2020)